CRT BIOMED

Unique Partnership
The relationship between CRT BioMed LLC and CRT Capital Group LLC was established to broaden the reach of CRT Capital's investment research efforts into companies centered in biotechnology, pharmacology and related areas. The relationship was founded on the view that investment research into these highly specific areas requires an extraordinary depth of experience and expertise generally not available in the normal course of institutional research undertakings. Through their educational backgrounds, active medical and consultation practices, and current hospital and academic appointments at Harvard Medical School, CRT BioMed's team brings to CRT Capital the ability to analyze with unique insight and deep comprehension the development, licensing and end-use opportunities of a wide range of biomed/pharma products. Beyond the contractual consultation relationship, CRT BioMed LLC is an independent entity and is not a part of CRT Capital Group LLC.

Insight and Expertise
CRT BioMed, led by Dr. Stuart Mushlin and currently comprised of doctors from Harvard Medical School, is designed to house additional senior medical and science professionals in selected specialties from other universities on a project-specific basis. The ability of CRT BioMed's team to assess the opportunities of both established products and products still in the development stage, when combined with CRT Capital's abilities to overlay sophisticated financial and investment analyses, enables CRT Capital to evaluate and anticipate both the operational and financial dynamics of biotechnology and pharmacology companies and the investment merits of the securities at each tier of the target companies' capital structures.

CRT BIOMED's team consists of four doctors from Harvard Medical School and two CRT Investment Professionals